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CHAPTER I
INTRODUCTION
Inflammation Background
The inflammatory response plays a very important role in maintaining the overall state of
the body and becomes activated when this state is disrupted by occurrence of tissue
damage or presence of pathogens (reviewed in Murphy, 2007). Functions of
inflammation include recruitment of effector cells to area of concern, release of
chemicals that promote repair, and local changes in blood vessels that cause increase in
permeability and size (reviewed in Murphy, 2007). These functions occur
simultaneously and are also synergistic in nature, enhancing the function of one another
to get the most optimal response (reviewed in Murphy, 2007). For example, the increase
in both permeability and size of blood vessels acts to create a barrier that prevents the
spread of the infection or damage (reviewed in Murphy, 2007). This change also allows
for more cells recruited by the inflammatory response to leave the circulatory system and
enter the tissue (reviewed in Murphy, 2007).
When working correctly, the inflammatory response slowly shuts off after repairs have
been completed due to expression of anti-inflammatory factors (Moustakas et al., 2002).
However, if the expression of pro-inflammatory factors fails to subside, chronic
inflammation can develop (reviewed in Coussens, 2002). Chronic inflammation has
become widely accepted as having a casual relationship to cancer with an estimated 1520% of all cancer deaths linked to inflammation (Balkwill et al, 2001; de Martel et al.,
2009). Examples of inflammatory diseases associated with cancer include inflammatory
bowel disease and colorectal cancer, bladder inflammation and bladder cancer, chronic
pancreatitis and pancreatic cancer, and gingivitis and oral squamous cell carcinomas
(Karin, 2006; Waldner et al, 2009; Wu et al., 2009).
Inflammation and Cancer
The relationship between chronic inflammation and cancer is dependent upon the
microenvironment established by inflammation (Luo et al., 2004; Singh et al., 2009;
Zhang et al., 2009). The microenvironment refers to the chemical factors and stroma
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present in an area with the stroma consisting of the extracellular matrix as well as
fibroblasts, endothelial cells and immunocytes (Rollins, 2006). The microenvironment
plays a pivotal role in the process of tumor initiation and promotion, both of which must
occur in order for cancer to develop (reviewed in Coussens, 2002). In order for a tumor
to arise, a normal cell must undergo some form of initiation that includes an alteration in
the cell’s DNA causing a change in its somatic state (Rous et al., 1941; Mackenzie et al.,
1941).
Initiation can occur independent of inflammation but it can also be caused by it (reviewed
in Coussens, 2002). The inflammatory response has the ability to alter cell’s DNA by
phagocytic cell’s production of reactive oxygen species (ROS) and reactive nitrogen
intermediates (RNI) that are used to fight against infection (Maeda et al., 1998). ROS
and RNI react to form peroxynitrite, a powerful oxidant and mutagenic agent that causes
DNA damage leading to the destruction of the infectious agent, but collateral damage can
also occur to the body’s cells (Maeda et al., 1998). Under normal conditions, a cell with
significant DNA damage would undergo apoptosis, however, factors released by the
inflammatory response include survival factors that prevent cell death (Lou et al., 2004).
Survival factors are released on the premise that in order to maintain the function of the
tissue in the context of a substantial number of cells being wounded, some cells must be
kept regardless of their damage (Chen et al., 2003). Factors are not selective in the cells
they affect and so they inadvertently prevent the apoptosis of the cells damaged by the
peroxynitrite (Chen et al., 2003).
Initiation is not sufficient by itself to cause cancer and it must be followed by a
promotion stage (reviewed in Coussens, 2002). Promotion involves repeated stimulation
of tissue turnover that can be brought about by various stimuli but in the end results in the
induction of cell proliferation (Grivennikov, 2010b). In the absence of proliferation,
cells can exist with DNA damage indefinitely without becoming neoplastic (Grivennikov,
2010b). The inflammatory response establishes a microenvironment optimal for tumor
progression by secreting factors supporting the tumor’s growth and survival (Chang et al.,
2004; Galon et al., 2006). Growth factors are released to enhance cell proliferation with
the intention of regenerating the tissue that was injured, but can end up increasing the
number of tumor cells (Singh et al., 2009; Mantovani et al, 2002). Along with inducing
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cell proliferation, many promotion events also function by recruiting inflammatory cells,
reducing DNA damage repair mechanisms and preventing cell death all of which are
involved in the inflammatory response and lead to a favorable state for neoplastic tissue
development (Mantovani et al, 2002; Singh et al., 2009; Zhang et al., 2009). The
inflammatory response produces such a supportive environment for cancer progression
that it has been observed to be induced through oncogenes (Borrello et al., 2005). For
instance in breast tumors, which have no previous underlying inflammation, an
inflammatory microenvironment in the tumor is produced and this supports the
importance of inflammation’s role in cancer (Mantovani, 2008).
The factors secreted by the inflammatory response are small molecules known as
cytokines that bind to receptors of cells affecting the behavior of that cell (reviewed in
Coussens, 2002). Macrophages, the predominant phagocytic cell recruited by the
inflammatory response, are attracted to the site of infection by concentration gradients
established by cytokines (Moser et al., 2004). Upon arrival to the tissue and exposure to
the infectious agent, macrophages become activated and begin secreting growth factors
and cytokines (reviewed in Coussens, 2002). Released cytokines attract more
macrophages that in turn become activated establishing a positive feedback loop that is
self-limiting under normal conditions, but in chronic inflammation can become
deregulated (Coussens et al., 2000; Lin et al., 2001; Mantovani et al., 1992)
Chemokines in carcinogenesis
A specific group of chemoattractant cytokines known as chemokines are responsible for
stimulating migration of cells to a location as well as causing their activation (reviewed in
Raman, 2007). Chemokines are a secreted type of cytokine that are relatively small and
characterized by cysteine motifs in their amino acid sequence (Bacon et al., 2002). They
can be categorized based upon their role in homeostasis and inflammation (Rossi, 2000).
Chemokines classified as homeostatic are found in normal tissues when no inflammatory
stimulus is present or are produced by cells that do not activate inflammation (Rossi,
2000). Inflammatory chemokines, as the name implies, are involved in the regulation of
inflammation (Rossi, 2000). However, these two categories are not mutually exclusive
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since the functions of certain chemokines are different based on the cell and tissue type
that they bind to (Rossi, 2000).
Chemokines have high specificity in the molecules they attract, but the same chemokine
can also interact with a variety of receptors (Zlotnik et al., 2000). These receptors vary
based upon cell type and the activation of certain cell types can depend more upon the
pattern of chemokines expressed (Weber et al., 2006). The function of a chemokine
depends upon the cell that the receptor it binds to is attached (reviewed in Raman et al.,
2007). Along with stimulating motility, these functions include angiogenesis, wound
healing, anti-apoptotic effects, proliferation, epithelial-mesenchymal transitions, pro and
anti-tumor responses, and Th1/Th2 development (Arenberg et al., 1997; Bonecchi et al.,
1998; Fernando et al., 2011; Zhang et al., 2012).
Chemokines have been found to be almost universally present in all cancers having
context-dependent role (Muller et al, 2001; Mukaida et al., 2012; Rollins, 2006).
Initially, they can be beneficial attracting immunocytes, such as macrophages, that can
destroy the tumor (Negus et al., 1997). However, the attraction of immunocytes later in
tumor development can have detrimental consequences (Leek et al., 1996). Majority of
cancerous cells secrete chemokines but they can also be released by stromal cells and can
act in a mutual paracrine manner between the tumor and stromal cell (Mizuno, et al.,
1994; Shih et al., 1994).
Chemokine: T helper cell development
Chemokines can also aid in the T cell polarization into Th1 or Th2 (Bonecchi et al.,
1998). Th1 and Th2 are both subsets of CD4+ T helper cells, but have different functions
(Mosmann et al., 1986; Sallusto et al., 1998). Th1 has anti-tumor functions activating
macrophages, managing the production of certain cytotoxic T cells and secreting
cytokines including the interferon IFN-γ (activates macrophages) and the interleukin IL2 (attracts white blood cells) (Cherwinski et al., 1987; Li et al., 1993; Mosmann et al.,
1986). Th2 opposes the anti-tumor functions of Th1 by decreasing the activity of
cytotoxic T cells (Cunha et al., 1992; Sallusto et al., 1998; Viola et al., 2006). It also
secretes IL-4 (causes differentiation of naive helper t cells to Th2), IL-5 (induces B-cell
growth and secretion), IL-10 (immunosuppressive) and IL-13 (anti-inflammatory and
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differentiation functions) (Mosmann et al., 1986; Swain et al., 1988). Th2 can also
induce macrophages into M2 macrophages that enhance expression of IL-10 further
enhancing tumor growth and development (Mantovani et al., 2002).
Another subset of T helper cell that is affected by chemokines is Th17, named because it
secretes IL-17 (Park et al., 2005). Its production of this cytokine along with others has
classified it as having pro-inflammatory functions (Fossiez et al., 1996). One of Th17’s
known functions is fighting extracellular infections and it is does this through cytokines it
releases (Aujla et al., 2007). These cytokines lead to the production of antimicrobial
peptides and recruitment of immunocytes (Liang et al., 2006; Liang et al., 2007). CCR6
is one of Th17’s principal receptors and is a specific marker for Th17 (Liao et al., 1999;
Singh et al., 2008). CCR6 is also present on a variety of other leukocytes, including
dendritic cells, T cells, B cells, neutrophils and Tregs (Baba et al., 1997; Greaves et al.,
1997; Yamashiro et al., 2000). It is also unique in that it only interacts with one specific
chemokine called CCL20 (Greaves et al., 1997).
CCL20 is expressed by a variety of cells including macrophages, dendritic cells, B cells,
T cells, and eosinophils (Hromas et al., 1997; Kleeff et al., 1999; Sullivan et al., 1999).
Many of the cells that secrete CCL20 also express CCR6 on their surface enabling
CCL20 to act in an autocrine manner in conjunction with its ability to function as a
paracrine agent (Kleeff et al., 1999). CCL20 is found in a variety of normal tissues such
as colon, pancreas, prostate, uterine cervix and skin classifying it as a homeostatic
chemokine (Cremel et al., 2006; Ghadjar et al., 2008; Kleeff et al.,1999; Varona et al.,
1998). It is also considered to be an inflammatory chemokine because it’s expression can
be induced in keratinocytes by proinflammatory cytokines TNF-α and/or IL-1β (Chabaud
et al., 2001; Fujiie et al., 2001; Nakayama et al., 2001). CCL20’s role in inflammation
includes binding to the cell surface receptor CCR6 on leukocytes causing them to migrate
(Greaves et al., 1997; Krzysiek et al., 2000; Liao et al., 1999; Varona et al., 2001).
It has previously been hypothesized that if tumor cells express both CCR6 and CCL20
then CCL20 might affect tumor development positively through autocrine and paracrine
mechanisms (Kleeff et al., 1999; Ghadjar et al., 2009). CCL20 secreted by tumor cells
could bind to CCR6 expressed on these same cells increasing their growth (Kleeff et al.,
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1999; Ghadjar et al., 2009). Conversely, CCL20 can interact with the stroma surrounding
tumor cells creating a more suitable microenvironment for the tumor (Kleeff et al., 1999;
Ghadjar et al., 2009). Due to CCL20 ability to stimulate migration in leukocytes, it is
also possible that it could aid in the metastasis of tumor cells (Greaves et al., 1997;
Ghadjar et al., 2009; Krzysiek et al., 2000; Liao et al., 1999; Varona et al., 2001). In a
study conducted by Ghadjar et al. on colorectal cancer patients, it was discovered that
CCR6 expression on tumor cells increased the risk of liver metastasis (Ghadjar et al.,
2006). Furthermore, Rubie et al. demonstrated that CCL20 levels were higher in patients
with colorectal cancer that had metastasized to the liver (Rubie, 2006). These studies
support the hypothesis that CCL20 has a role in cancer development. The aim of this
study is to define CCL20’s impact on cancer, and since CCL20 is a Th17 specific
chemokine, it will allow us to shed light onto Th17’s role in cancer. Although the
contribution of Th1 and Th2 in carcinogenesis has been well established, Th17’s function
in cancer development has yet to be identified.

CHAPTER II
MATERIALS AND METHODS
Establishing CCL20 expressing tumor cells: An 03R cell line derived from normal
balb/c mice keratinocytes that had undergone initiation forming a squamous cell
carcinoma derivative was used to generate a CCL20 inducible cell line (Han et al., 1992;
Kulesz-Martin et al., 1986; Kulesz-Martin et al., 1988). The 03R cell line was
transfected with a CCL20 plasmid. The plasmid contained CMV, a general promoter for
CCL20, tetracycline repressor element (TRE), which is a DNA element for tetracycline
repressor to bind to, and tetracycline repressor (TR), which binds to TRE when
tetracycline is absent (see figure 1). ELISA was used to measure the CCL20 expression
levels of clones generated.
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Fig. 1. A CCL20 over expressing
tumor cell was established through
a tetracycline inducible system.
When tetracycline is not present,
TR is allowed to bind to TRE
blocking CMV’s ability to promote
CCL20 and therefore, CCL20
expression is repressed. When
tetracycline is present, it binds to
TR allowing CMV to promote
CCL20 and CCL20 is expressed.
Analysis of CCL20 expression of transfected tumor cells by ELISA: Tetracycline
medium was collected from each clone and frozen. Then .1µL of tetracycline was added
to the medium of each clone and allowed to sit overnight. The following morning, the
medium was collected. CCL20 levels were of the medium with tetracycline and the
medium without it were measured using an ELISA from R&D systems. Results are
expressed as picograms per milograms.
Evaluating tumorigenicity of CCL20 expressing tumor cells in vivo: Balb/c mice were
housed in Oregon Health and Science University’s Barrier under pathogen free
conditions and the animal study was performed in accordance to Oregon Health and
Science University’s Institutional Animal Care & Use Committee (IACUC). A 1:1
mixture of 0.1mL solution of CCL20 expressing tumor cells and 03R parental cell line
were injected subcutaneously into the backs of neonates. CCL20 expression was induced
by tetracycline treatments that were administered in 5% sucrose water at a concentration
of 0.3% tetracycline.
The tumors on the mice were measured twice a week and the size was calculated by the
formula: tumor length x tumor width. Tumor size was measured until it reached a size of
approximately 2x2cm upon which they mice were terminated under the protocol
approved by OHSU’s IACUC. Upon termination, the tumor was removed and placed in
a formaldehyde solution for one day and then replaced with 70% ethanol. The tumors
were then sent to OHSU’s core were each tumor was sectioned and stained with H&E.
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Evaluating CCL20 expression in human HNSCC: ABC staining was performed on 20
head and neck squamous carcinoma samples along with normal uninvolved human skin
to act as a negative control and psoriatic skin (Liu et. al., 2010) to use as a positive
control. Of the 20 samples, 8 were tumor samples without positive nodes, six had positive
nodes, and the remaining six had metastasized. In order to prevent non-specific binding,
the slides were incubated in PAP (PBS, 0.05% sodium azide, 2% BSA) for one hour.
The slides were then incubated overnight at 4oC with a goat primary antibody. The
secondary antibody used was a CCL20 anti-goat (G-20) manufactured by Santa Cruz.
The ABC staining was done using a Vectastain ABC kit from vector labs and the slides
were then counterstained with hematoxylin.

CHAPTER III
RESULTS
Generation of Tetracycline inducible CCL20 tumor cell lines
In order to evaluate CCL20’s affects on tumorigenesis, we generated a cell line that could
be induced to over express CCL20 using a tetracycline inducible system. A tumorigenic
cell line (03R) was chosen as the line to transfect due to its similarity to SCCs. We
selected 48 stable cell clones to test CCL20 inducibility by tetracycline. The CCL20
expression was measured by CCL20 ELISA. The clones with more than 10 fold CCL20
induction upon tetracycline treatment were selected (Figure 2A). A total of 3 clones were
found to over express CCL20: clones 1, 11, and 14, with clone 11 being induced to
express CCL20 approximately 30 times more than without induction (figure 1A). The
highest CCL20 expression (900 pg/ml) is within the range of CCL20 expression in
normal keratinocytes (291) treated with TNFa (Figure 2B).
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B
A
Fig. 2. CCL20 levels evaluated by ELISA. Clones 1, 11 and 14 expressed CCL20 at least
10 times more with induction than without (A). Clone 11 underwent the highest CCL20
expression (900 pg/ml) and that is within the range of CCL20 expression in normal
keratinocytes (291) treated with TNFa (B).
Evaluation of 03R tumorigenesis in response to CCL20 expression
We explored CCL20’s role in tumor development in vivo by inoculating BALB/c
neonates subcutaneously with a 1:1 mixture of clone 11 and the 03R parental cell line
(xxx cells total). 03R parental cell line was used to inoculate the mice in case clone 11
had undergone a loss in tumorigenicity after undergoing transfection. The mice were
split into two groups with one receiving tetracycline treatments starting at three weeks
after inoculation and masses that developed were measured. Mice that were inoculated
with the mixture of parental 03R cell line and clone 11 along with tetracycline treatments
developed larger masses, as seen in Figure 3A. However, because of the development of
hematocysts which compromised assessment of tumor development, the weight of the
tumors for each group were measured after the masses were dissected. Figure 3B shows
that the group of mice treated with tetracycline followed a general trend of having larger
masses than the group that did not receive tetracycline treatment.
Although there was a tendency of increased size of masses at the injection sites, the
tumor weights from 03R/CCL20 with or without tetracycline was not statistically
significant by 2 tailed Student t test. The trend of increased tumor growth upon CCL20
expression suggests that CCL20 has a possible role in aiding tumor development. Further
study with increased number of mice is needed to define the role of CCL20 in
carcinogenesis.
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A

B

C
Clone 11 control
Clone 11 with tetracycline
Fig. 3. Evaluate the effect of CCL20 on 03R tumorigenicity. Mice receiving tetracycline
treatments had larger masses measured on their backs (A). These mice were also found
to have heavier tumors (B). The histology of 03R tumors are shown in the lower panel
(C). The mice that were given tetracycline appear to have more immunocyte infiltration
into the tumor tissue.
The tumors collected from the mice were stained with H&E to see if there was any
histological difference between the mice receiving tetracycline treatments and those that
did not (Figure 3C). The tumors of the mice given tetracycline treatments appear to have
more infiltration of immunocytes into the tumor cells than the tetracycline negative mice
whose immunocyte cells are slightly more separated from the tumor cells. However,
there is no significant correlation between the infiltration of immunocytes versus tumor
growth. Apparent differences were small, indicating that CCL20 effects on tumor
growth, if any, may require more samples in order to establish a correlation.
Evaluation of CCL20 expression in human head and neck carcinoma
CCL20 expression was evaluated in head and neck SCCs. Three different groups of SCC
were used: one group without positive nodes, a second group with positive nodes, and a
final group of samples that had metastasized (staining results summarized in Figure 4).
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No Positive
Nodes
Positive Nodes
Metastasis

Strong
Positive

Positive

Negative

Total Number of
Samples

1
1
-

7
3
3

2
3

8
6
6

Strong Positive
Positive
Negative
Fig. 4. CCL20 staining intensity in human HNSCC. Top panel is the summary of immunostaining
results. Tumor samples without positive nodes all stained positive for CCL20 while more
variation of CCL20 staining was seen in tumor samples with positive nodes and tumor samples
that had metastasized. The lower panel contains representative staining images of HNSCC
samples stained with CCL20.

All of the tumor samples from the group with no positive nodes stained positive for
CCL20 with one of them staining very strongly. Samples from the groups with positive
nodes and those that had metastasized, showed more variability in CCL20 expression.
Half of the samples with positive nodes stained positive for CCL20. Of the remaining
half, one stained strongly positive and two were negative. Of the tumor samples that had
metastasized, half stained positive and the other half of the samples were negative.
Staining of CCL20 shows that its expression is present throughout cancer progression
including in the earliest stages tested, since all tumors without positive nodes stained
positive for it.

CHAPTER IV
DISCUSSION
In this study, we provided experimental evidence regarding association of CCL20 with
tumorigenesis. Examining CCL20 in the context of SCC, we found that when CCL20
was over expressed, tumor size tended to increase; however this did not reach statistical
significance. Enhanced tumor size could be attributed to a number of possible functions
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related to CCL20. It has been established that CCL20 acts as a chemoattractant
recruiting immunocytes to areas that exhibit high concentrations of CCL20 (Ghadjar et
al., 2009). The increase in tumor size could be explained by an increase in immunocytes
that were recruited to the tumor by CCL20. Due to cancer’s ability to hijack the
inflammatory response and use it for its advantage, the immunocytes may be acting to aid
in tumor cell progression or it is possible they are functioning to fight the tumor cells.
Several limitations of our study leave CCL20’s and Th17’s functional roles unidentified
and a clear relationship between CCL20 and cancer has yet to be established.
Specifically, long-term studies are needed in order to evaluate the influence CCL20 on
tumorigenesis.
When the histology of the tumors from the in vivo study were examined, it appeared that
mice treated with tetracycline had increased infiltration of immunocytes in tumors
compared to mice that did not receive treatment. However, there were no significant
correlations between the infiltration of immunocytes versus tumor growth in the small
sample sizes of our study. Furthermore, we do not know what types of immunocytes
infiltrated tumor tissue. It has been established that CCL20 recruits Th17, Treg, and B
cells, making it rational to conclude that these are the immunocytes present in samples in
which CCL20 was over-expressed (Greaves et al., 1997; Krzysiek et al., 2000; Liao et al.,
1999; Varona et al., 2001). However, the function of these immunocytes has yet to be
defined, because, as stated above, they could be aiding in tumor development or
impeding it.
In addition, a limitation of this in vivo study was the unexpected development of
hematocysts that interfered with the measurement of tumors. The study was initially
designed to last for a longer period of time in order for us to observe CCL20’s more
extended effect on tumor growth and in addition, tumor metastasis. The study was
significantly shorter than what is necessary to observe metastasis. There are a few
possible causes for the development of hematocysts, including the invasiveness of the
03R tumor cell line used to inoculate the mice. A previous pilot study we conducted
inferred that clone #11 had undergone a loss in tumorigenicity after undergoing
transfection. This is why in the following experiments we used a mixture of parental
03R, which was expected to produce tumors in ~100% of injection sites, with clone 11, to
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provide a source of CCL20 in the tumor environment, to inject the mice. However,
03R’s ability to generate tumors may be have already been maximal, minimizing the
impact of CCL20, or the manipulation of cells required for our experiment may have
stimulated production of the hematocysts. A possible solution for this problem could be
simply increase the 03R cell ratio in the mixture used to inject the mice. An optimization
study that utilized varying dilutions would need to be conducted in order to determine the
appropriate concentration.
Furthermore, although significant CCL20 induction was achieved in 03R clone #11
(more than 10 fold induction), the CCL20 induction level was far less than the CCL20
level produced from normal keratinocytes in culture treated with TNFα (see Figure 2b in
results section). Future tumorigenesis studies with higher CCL20 induction (equivalent
to that in stimulated normal keratinocytes) in the 03R tumor cell are needed to define the
pathological role CCL20 in tumorigenesis.
Staining of CCL20 in human head and neck SCC samples showed that CCL20 expression
is present throughout cancer progression including in the early stages prior to lymph node
involvement. This is consistent with the initial reports from our laboratory showing
Trim32, a positive regulator of NFkB and CCL20, at the initiation stages of
carcinogenesis (Horn et al., 2004). While staining of CCL20 in the SCC samples
establishes the presence of CCL20 it does not define its role. Even so, when taken in
conjunction with the current in vivo study, it is possible to infer that CCL20’s presence
throughout cancer progression may act to increase tumor size. CCL20 expression was
found to be consistently present on tumors without positive nodes, which represent
tumors in the beginning stages of cancer. Therefore, its expression could contribute to
the microenvironment of the tumor in such a way that is supportive of the tumor
progression.
Further studies are needed in order to establish a relationship between cancer and CCL20.
If a relationship is found, it could be used to generate new therapy techniques in the
treatment of certain types of cancer. For example, if a positive relationship is established,
treatments could be created to inhibit CCL20 expression or to target CCL20’s ability to
act as a ligand to CCR6. In contrast, if a negative association is discovered, treatments
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could focus on increasing CCL20 expression in hopes of hindering cancer development.
By further defining CCL20’s function in cancer, it will ultimately help us to characterize
the role of Th17 cells in cancer.
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